• "Despite our 'science,' the art remains elusive to us. Whither the White Knight?"

-Leerink Swann analyst Joshua Schimmer, suspending his rating on Genzyme as Sanofi takeover rumors swirl

• "It's surprising to us that the market seems to demand from drug companies a seamless progression of earnings when a major drug faces a patent expiration. At some point, we feel investors will realize this is a fact of life in the drug industry."

-Jefferies & Co. Inc. analyst Corey Davis on Cephalon Inc.'s stock drop despite solid quarterly earnings

• "What's rare about biotech technologies is that so few ultimately deliver."

-George Yancopoulous, executive vice president, chief scientific officer and president of Regeneron Research Laboratories